India could be staring at a national health crisis in the backdrop of its continuing massive reliance on Chinese active pharmaceutical ingredients (APIs), including those used in drugs for high-burden diseases such as diabetes and cardiovascular ailments, according to a report by the professional services firm KPMG and the Confederation of Indian Industry (CII).
China API Juggernaut Rolls On But Can India Recoup?
Report: India’s huge dependence on Chinese active pharmaceutical ingredients (APIs), including in high disease burden areas, poses heightened risks to its health security and requires “urgent interventions.”
More from Manufacturing
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
J&J followed in the footsteps of Lilly and Merck, which have announced multibillion-dollar investments in US manufacturing since Donald Trump’s inauguration.
• By
A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.